LAX travelers potentially exposed to positive measles case
The traveler arrived on China Airlines Flight 008 at the Tom Bradley International Terminal on Aug. 2, officials said. Anyone who was in Terminal B between 9:30 p.m. Aug. 2 and 12:35 a.m. Aug. 3 may have been exposed.
Any passengers who were seated next to this person on their flights will be notified of their exposure by local public health agencies.
The Los Angeles County Department of Public Health urges anyone potentially exposed to check their vaccination status, monitor for symptoms for 21 days, and stay home if they develop symptoms, which can include high fever, cough, runny nose, red eyes and a rash.
'With measles outbreaks reported both in the United States and abroad, it is important for everyone to ensure they are fully vaccinated, especially before traveling,' the department said.
Los Angeles County Health Officer Dr. Muntu Davis said measles is highly contagious through the air and on surfaces, and spreads particularly easily among those who are unvaccinated or have never had it in the past.
'Measles can lead to severe disease in young children and vulnerable adults. The best way to protect yourself and your family from infection is with the highly effective measles vaccine,' Davis said.
More information is available at ph.lacounty.gov/measles.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
US airlines' shares jump as airfare data signals improving pricing power
(Reuters) -Shares of major U.S. carriers jumped on Tuesday after upbeat airfare data for July signaled improving pricing power for the industry, as airlines bring capacity in check to align with a soft demand environment. Shares of legacy carriers United Airlines, American Airlines and Delta Air Lines jumped nearly 10% each, while budget rival Southwest Airlines gained 4% in afternoon trading. Smaller peers Alaska Air and JetBlue Airways rose about 10% each and low-cost carrier Frontier Group surged 22%. Data from the Labor Department's Bureau of Labor Statistics on Tuesday showed airfares rose 4% in July after slipping 0.1% in June, marking their first increase in six months. Uncertainty stemming from President Donald Trump's sweeping tariffs and budget cuts has prompted travelers to curb discretionary spending and reassess plans. A soft demand environment, particularly from budget-conscious domestic travelers, had forced carriers to discount fares, squeezing margins despite summer typically being their peak money-making season. Airlines have since been trimming seats on offer and readjusting routes to keep their pricing power in control and shield margins. During their second-quarter earnings calls in July, major executives expressed confidence in the industry's ability to cut capacity and boost airfares in the latter part of the year.
Yahoo
28 minutes ago
- Yahoo
MedTech Manufacturer Juvent Joins the Inc. 5000 List of America's Fastest-Growing Private Companies
With Three-Year Revenue Growth of 552%, This Marks Juvent's First Time on the List Juvent Joins Inc. 5000 The Juvent Micro-Impact Platform CHATTANOOGA, Tenn., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that Juvent, makers of the Juvent Micro-Impact Platform, is in the top 15% of the prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. 'Being ranked #757 is a testament to the life-changing impact our technology has on people's health,' said Rush Simonson, Juvent Chairman & CEO. 'We're proud to assemble every unit right here in Tennessee, and even prouder to see it helping people worldwide to feel better every day. This isn't just a win for Juvent, it's a win for everyone who refuses to let pain dictate their life.' Juvent focuses on regenerative medicine, enabling the body's own systems to repair themselves and speed healing. The Juvent technology was originally developed by Jack Ryaby, the inventor of the Biomet EBI Bone Healing System and the EXOGEN Ultrasound Bone Healing System, both of which are still widely used today. The Juvent Micro-Impact Platform is an FDA-registered, Class I medical device that delivers a patented, resonant, low-magnitude, high-frequency mechanical signal through the soles of the feet while the user stands on it. This gentle technology is clinically shown to promote bone strength, improve circulation, reduce pain, and activate key cellular processes, including stimulating mesenchymal stem cell production. Just 20 minutes a day helps support overall wellness, especially for those managing chronic conditions like poor bone health, lymphedema, neuropathy, and joint pain. Since 2011, the Juvent platform has been trusted by thousands, including tennis Olympic gold medalist Mike Bryan, Baltimore Ravens linebacker Ray Lewis, and high-profile personalities like Steve Harvey to speed recovery, reduce pain, and improve daily well-being. Juvent's unique technology has also been featured on nationally recognized health platforms, including Dr. Gundry's and Dr. Drew Pinsky's podcasts. The Juvent platform has been studied by top institutions and is used in both clinical and home settings. Double-blinded, placebo-controlled clinical trials involving the Juvent platform have been conducted in collaboration with renowned organizations such as St. Jude and Harvard and featured in publications like JAMA Oncology. Unlike the common high-powered whole-body vibration platforms, Juvent stands apart through its patented, resonance-based technology. The smart device automatically determines each user's ideal resonant frequency based on hydration to deliver a personalized dosage of micro-impacts. This precision approach is key to why Juvent is safe for children, adults, and seniors—and highly effective for all ages. Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit About JuventJuvent delivers clinically validated solutions to improve musculoskeletal health. Our patented Micro-Impact Platform has clinically demonstrated the ability to help users manage and improve their musculoskeletal health noninvasively. Additionally, our technology helps users decrease joint pain and increase lymphatic drainage. Juvent's Micro-Impact is an essential ingredient for total health and vitality, a 'Vitamin of Exercise™.' Photos accompanying this announcement are available at: CONTACT: Contact: Sarah Rhodes Info@ (423) 635-7601Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Hand soaps, cleansers voluntarily recalled over bacteria contamination
A New Jersey-based medical care and skin care products manufacturer is voluntarily recalling multiple types of hand soap, cleanser and antiseptic products due to bacteria contamination. DermaRite Industries, LLC announced a recall of its DermaKleen antiseptic lotion soap with vitamin E in 1,000-milliliter and 800-milliliter sizes, as well as KleenFoam antibacterial foam soap with aloe vera (1,000-milliliter sizes), DermaSarra external analgesic (7.5-ounce sizes), and PeriGiene antiseptic cleanser (7.5-ounce sizes), all of which were distributed in the U.S. and Puerto Rico. Impacted products have expiration dates ranging from July 2025 to February 2027. A full list of affected lot and reorder numbers can be found here. The company recall announcement, dated Aug. 8, was also shared on the U.S. Food and Drug Administration website over the weekend. DermaRite said in its announcement that the impacted products are contaminated with Burkholderia cepacia, a type of bacteria that can cause serious or life-threatening infections. "The contaminated products may be used by immunosuppressed individuals or by people attending to immunosuppressed individuals," DermaRite stated. "In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis." Nearly 200,000 kids play kitchens recalled after 1 reported death The Centers for Disease Control and Prevention states that Burkholderia cepacia, also referred to as B. cepacia or Bcc, often spreads through soil and water sources, in addition to contaminated surfaces and products and through person-to-person contact. When someone is infected with the bacteria, they may not exhibit any symptoms. If they do show symptoms, they may experience respiratory issues or a fever or fatigue. High Noon voluntarily recalls some vodka seltzer drinks that were mislabeled as Celsius energy drinks People who are immunocompromised or those with chronic lung conditions including cystic fibrosis are at higher risk of becoming infected with B. cepacia, according to the CDC. The bacteria can also be resistant to antibiotics, making infections difficult to treat, the CDC states. DermaRite said it has already notified its distributors and customers via e-mail "to immediately examine available inventory" and to destroy any recalled products "in accordance with each facility's process." The company said it has not received any reports of adverse reactions in connection with the recall. Anyone experiencing symptoms after product use should consult with their health care provider and report adverse reactions to the FDA's MedWatch Adverse Event Reporting program, it added. Customers with questions or those in need of further information on the recall can contact DermaRite by phone at (973) 569-9000, extension 104, Monday through Friday from 9 a.m. to 5 p.m. EST, or via email at ABC News has reached out to DermaRite Industries for comment. Solve the daily Crossword
